Bayer acquires Vividion for $1.5B

By The Science Advisory Board staff writers

August 5, 2021 -- Bayer has acquired Vividion Therapeutics for an upfront consideration of $1.5 billion and potential success-based milestone payments of up to $500 million.

Vividion is focused on the identification of drug candidates for proteins that are considered undruggable. The company's chemoproteomic screening platform can identify previously unknown binding pockets on well-validated protein targets by screening chemical probes against the entire human proteome to assess selectivity.

Vividion's platform produces a variety of small molecule therapies across many indications, including oncology and immunology. The company's lead programs for precision oncology and immunology targets comprise a transcription factor Nrf2 (nuclear factor erythroid 2-related factor) antagonist for the potential treatment of Nrf2 mutant cancers, as well as Nrf activators for various inflammatory diseases such as irritable bowel disease, among other preclinical programs.

Once the transaction closes in the third quarter, Bayer will own the full rights to Vividion's discovery platform that consists of three integrated components: a novel chemoproteomic screening technology, an integrated data portal, and a proprietary chemistry library. Vividion will continue to operate as an independent organization on an arm's length basis.

The acquisition strengthens Bayer's small molecule capabilities, the firm said.

Vividion raises $135M for immuno-oncology small-molecule drugs
Vividion Therapeutics has raised $135 million in financing to support the development of its pipeline of precision oncology and immunology programs.
Bayer media day focuses on cell, gene, oncology channels
Bayer highlighted its focus on cell, gene, and oncology pipelines during its virtual Pharma Media Day in Germany.
Bayer acquires Asklepios to advance gene therapies
Bayer has agreed to pay $2 billion to acquire Asklepios BioPharmaceutical, a U.S.-based biotechnology company specializing in gene therapies.
Vividion, Roche partner for small-molecule drug discovery
Biotechnology company Vividion Therapeutics has signed an exclusive worldwide option and license agreement with Roche.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter